In addition to the six EGFR-mutant lines tested above (erlotinib-sensitive and -resistant pairs of PC9, HCC827, and HCC4006 cells), we added one additional engineered HCC827 cell expressing exon 19 deletion E746-A750 plus T790M, as well as 10 lung cancer cell lines lacking EGFR mutations (Soh et al, 2009). This evidence concerns the gene EGFR and lung carcinoma.